Immutep Limited (PRRUF)
- Previous Close
0.2400 - Open
0.2369 - Bid --
- Ask --
- Day's Range
0.2400 - 0.2400 - 52 Week Range
0.1400 - 0.3100 - Volume
3,000 - Avg. Volume
325 - Market Cap (intraday)
285.319M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.
www.immutep.comRecent News: PRRUF
Performance Overview: PRRUF
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRRUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRRUF
Valuation Measures
Market Cap
271.18M
Enterprise Value
205.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.85
Enterprise Value/Revenue
803.42
Enterprise Value/EBITDA
-5.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.70%
Return on Equity (ttm)
-42.12%
Revenue (ttm)
3.93M
Net Income Avi to Common (ttm)
-40.5M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
103.73M
Total Debt/Equity (mrq)
1.40%
Levered Free Cash Flow (ttm)
-26.61M
Company Insights: PRRUF
PRRUF does not have Company Insights